Abstract:Through the combined use of (18)F-fallypride positron emission tomography and magnetic resonance imaging this study examined the neural mechanisms underlying the attentional deficits associated with attention deficit/hyperactivity disorder and their potential reversal with a single therapeutic dose of methylphenidate. Sixteen adult patients with attention deficit/hyperactivity disorder and 16 matched healthy control subjects were positron emission tomography and magnetic resonance imaging scanned and tested on a computerized sustained attention task after oral methylphenidate (0.5 mg/kg) and placebo administration in a within-subject, double-blind, cross-over design. Although patients with attention deficit/hyperactivity disorder as a group showed significant attentional deficits and reduced grey matter volume in fronto-striato-cerebellar and limbic networks, they had equivalent D2/D3 receptor availability and equivalent increases in endogenous dopamine after methylphenidate treatment to that observed in healthy control subjects. However, poor attentional performers drawn from both the attention deficit/hyperactivity disorder and the control groups had significantly reduced left caudate dopamine activity. Methylphenidate significantly increased dopamine levels in all nigro-striatal regions, thereby normalizing dopamine levels in the left caudate in low performers. Behaviourally, methylphenidate improved sustained attention in a baseline performance-dependent manner, irrespective of diagnosis. This finding was accompanied by an equally performance-dependent effect of the drug on dopamine release in the midbrain, whereby low performers showed reduced dopamine release in this region. Collectively, these findings support a dimensional model of attentional deficits and underlying nigro-striatal dopaminergic mechanisms of attention deficit/hyperactivity disorder that extends into the healthy population. Moreover, they confer midbrain dopamine autoreceptors a hitherto neglected role in the therapeutic effects of oral methylphenidate in attention deficit/hyperactivity disorder. The absence of significant case-control differences in D2/D3 receptor availability (despite the observed relationships between dopamine activity and attention) suggests that dopamine dysregulation per se is unlikely to be the primary cause underlying attention deficit/hyperactivity disorder pathology in adults. This conclusion is reinforced by evidence of neuroanatomical changes in the same set of patients with attention deficit/hyperactivity disorder.

The 5-HTTLPR polymorphism of the serotonin transporter gene and short term behavioral response to methylphenidate in children with ADHD

Pharmacogenetics of Methylphenidate Response in Preschoolers with ADHD

Association of Norepinephrine Transporter Gene with Methylphenidate Response.

The study of the association between COMT polymorphisms and methylphenidate response in the treat-ment of attention deficit hyperactivity disorder

Genetic evidence for the association of the hypothalamic-pituitary-adrenal (HPA) axis with ADHD and methylphenidate treatment response

Dopamine Transporter and CYP2D6 Gene Relationships with Attention-Deficit/Hyperactivity Disorder Treatment Response in the Methylphenidate and Atomoxetine Crossover Study

Placebo-related improvement with methylphenidate treatment in children with ADHD

CES1 and SLC6A2 Genetic Variants As Predictors of Response To Methylphenidate in Autism Spectrum Disorders

Contribution of 5-HT2A receptor gene -1438A>G polymorphism to outcome of attention-deficit/hyperactivity disorder in adolescents

An international multicenter association study of the serotonin transporter gene in persistent ADHD

The effects of methylphenidate on cognitive function in children with attention-deficit/hyperactivity disorder

No Significant Association between the Alpha-2A-Adrenergic Receptor Gene and Treatment Response in Combined or Inattentive Subtypes of Attention-Deficit Hyperactivity Disorder

A Positron Emission Tomography Study of Nigro-Striatal Dopaminergic Mechanisms Underlying Attention: Implications for ADHD and Its Treatment.

Effect of methylphenidate on functional controllability: a preliminary study in medication-naïve children with ADHD

Synaptosomal-Associated Protein 25 Gene Polymorphisms Affect Treatment Efficiency of Methylphenidate in Children With Attention-Deficit Hyperactivity Disorder: An fNIRS Study

Association Between Single-Dose and Longer Term Clinical Response to Stimulants in Attention-Deficit/Hyperactivity Disorder: A Systematic Review of Randomized Controlled Trials

New Insights on the Effects of Methylphenidate in Attention Deficit Hyperactivity Disorder

An Open-Label Trial of Methylphenidate Treating Sluggish Cognitive Tempo, Inattention, and Hyperactivity/Impulsivity Symptoms Among 6- to 12-Year-Old ADHD Children: What Are the Predictors of Treatment Response at Home and School?

ASSOCIATION ANALYSIS OF SEROTONIN TRANSPORTER PROMOTER GENE POLYMORPHISM WITH ADHD AND RELATED SYMPTOMATOLOGY

Effects of Methylphenidate on Default-Mode Network/Task-Positive Network Synchronization in Children With ADHD

Adrenergic Neurotransmitter System Transporter and Receptor Genes Associated with Atomoxetine Response in Attention-Deficit Hyperactivity Disorder Children